CpG oligodeoxynucleotides as mucosal adjuvants
Authors:
Open Access
- 4 March 2015
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (3) , 755-760
Abstract
Bacterial DNA comprising palindromic sequences and containing unmethylated CpG is recognized by toll-like receptor 9 of plasmacytoid dendritic cells (pDCs) and induces the production of interferon-α and chemokines, leading to the activation of a Th1 immune response. Therefore, synthetic equivalents of bacterial DNA (CpG oligodeoxynucleotides) have been developed for clinical applications. They are usually phosphorothioated for in vivo use; this approach also leads to adverse effects as reported in mouse models.Mucosal vaccines that induce both mucosal and systemic immunity received substantial attention in recent years. For their development, phosphodiester-linked oligodeoxynucleotides, including the sequence of a palindromic CpG DNA may be advantageous as adjuvants because their target pDCs are present right there, in the mucosa of the vaccination site. In addition, the probability of adverse effects is believed to be low. Here, we review the discovery of such CpG oligodeoxynucleotides and their possible use as mucosal adjuvants.Keywords
This publication has 32 references indexed in Scilit:
- Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCGImmunity & Ageing, 2013
- Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery systemInternational Journal of Nanomedicine, 2012
- A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural PropertiesOligonucleotides, 2010
- Plasmacytoid Dendritic Cells Delineate Immunogenicity of Influenza Vaccine SubtypesScience Translational Medicine, 2010
- Vaccine adjuvants revisitedVaccine, 2007
- Therapeutic potential of Toll-like receptor 9 activationNature Reviews Drug Discovery, 2006
- Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2001
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Oligonucleotide Sequences Required for Natural Killer Cell ActivationJapanese Journal of Cancer Research, 1992
- Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigensVaccine, 1988